Barinthus Biotherapeutics Plc. Overview
Valuation check: BRNS's P/E ratio is -0.43, below the Healthcare sector average of 27.42.
Get informed when a big investor buys or sells
+ Follow-0.43
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
As of the most recent data, BRNS shows a P/E ratio of -0.43. That is below the Healthcare sector average of 27.42. Scroll down for historical charts and peer comparison views.
The Healthcare sector average P/E ratio is about 27.42. Barinthus Biotherapeutics Plc. is at -0.43, which is lower that average. That is roughly 101.6% below the sector mean. Use the comparison chart on this page to see how BRNS stacks up against individual peers as well.
Investors watch BRNS's P/E ratio because it compresses price and fundamentals into one number that is easy to compare across companies and over time. Barinthus Biotherapeutics Plc.'s latest reading is -0.43. Combining that with growth, ROE, and debt metrics usually beats relying on a single multiple.
Besides this p/e ratio page, Stockcircle has Barinthus Biotherapeutics Plc.'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect P/E ratio (currently -0.43) with ownership activity and broader fundamentals.
The Healthcare average P/E ratio is about 27.42, while BRNS is at -0.43. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.
